Expediting Approval of Novel Inflammatory Dermatology Therapeutics in Europe with Robust Clinical Evidence and Superior Efficacy

Time: 9:00 AM – 4:45 PM

Venue Details: Hotel Palace Berlin, 45 Budapester Straße, Berlin, 10787, Germany

Prices:
Industry – Conference + 2 Workshops: EUR 3797.00,
Industry – Conference + 1 Workshop: EUR 3298.00,
Industry – Conference Only: EUR 2799.00,
Service Provider – Conference + 2 Workshops: EUR 4697.00,
Service Provider – Conference + 1 Workshop: EUR 4098.00,
Service Provider – Conference Only: EUR 3499.00

Speakers: Anna-Lena Spetz, CSO, TIRmed, Betsy Hughes- Formella, Co-Founder and Chief Scientific Officer, Dermaliq Therapeutics, David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd, Elena Rizova, Vice President, Head Medical Affairs, Biogen Intercontinental Region, Biogen, Elisabeth Riedl, Associate Professor – Department of Dermatology, Medical University of Vienna, Farzan Solimani, Physician, Charite, Universitatsmedizin Berlin, Guido Wurth, Global Head of Programs, Affibody AB, Jonathan Zalevsky, Chief Research and Development Officer, Nektar Therapeutics, Kim Kjoller, Chief Executive Officer, Union Therapeutics, Kristian Reich, Chief Scientific Officer, MoonLake Immunotherapeutics AG, Laurence Cheng, Vice President, RAPT Therapeutics, Mathias Schmelcher, Senior Scientific Advisor, MICREOS, Ofer Toledano, Vice President – Research and Development, Sol Gel Technologies, Pnina Fishman, Executive Chairman and CSO, Can-Fit, BioPharma Ltd, Robert Rissmann, Professor – Translational Dermatology, Leiden University, Simmi Wiggins, Regional Lead – Immunology and Medical, Sanofi, Tamar Ben Yedidia, CSO and clinical management, Scinai Immunotherapeutics, Thorsten Thormann, Stretegic Advisor, Independant Consultant, Todd Krueger, President and CEO, AOBiome